240 related articles for article (PubMed ID: 10895822)
21. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group.
Terrier-Lacombe MJ; Guillou L; Maire G; Terrier P; Vince DR; de Saint Aubain Somerhausen N; Collin F; Pedeutour F; Coindre JM
Am J Surg Pathol; 2003 Jan; 27(1):27-39. PubMed ID: 12502925
[TBL] [Abstract][Full Text] [Related]
22. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate.
Díaz-Cascajo C; Bastida-Iñarrea J; Borrego L; Carretero-Hernández G
J Cutan Pathol; 1995 Aug; 22(4):304-9. PubMed ID: 7499569
[TBL] [Abstract][Full Text] [Related]
23. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Cohen PR; Rapin RP; Farhood AI
Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
[No Abstract] [Full Text] [Related]
24. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
25. Benign fibrous histiocytoma (dermatofibroma) of the face: clinicopathologic and immunohistochemical study of 34 cases associated with an aggressive clinical course.
Mentzel T; Kutzner H; Rütten A; Hügel H
Am J Dermatopathol; 2001 Oct; 23(5):419-26. PubMed ID: 11801774
[TBL] [Abstract][Full Text] [Related]
26. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
27. Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases.
Shah KK; McHugh JB; Folpe AL; Patel RM
Am J Surg Pathol; 2018 Mar; 42(3):413-419. PubMed ID: 29240584
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
29. Atrophic and plaquelike dermatofibrosarcoma protuberans.
Davis DA; Sánchez RL
Am J Dermatopathol; 1998 Oct; 20(5):498-501. PubMed ID: 9790114
[TBL] [Abstract][Full Text] [Related]
30. [Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].
Zhang J; Wu N; Xia C; Wei X; Shi QL; Zhou XJ; Ma J
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):753-7. PubMed ID: 24447553
[TBL] [Abstract][Full Text] [Related]
31. Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinicopathologic comparison.
Zelger B; Sidoroff A; Stanzl U; Fritsch PO; Ofner D; Zelger B; Jasani B; Schmid KW
Am J Surg Pathol; 1994 Jul; 18(7):677-86. PubMed ID: 8017562
[TBL] [Abstract][Full Text] [Related]
32. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
Mentzel T; Schärer L; Kazakov DV; Michal M
Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
34. A cutaneous case of giant cell angiofibroma occurring with dermatofibrosarcoma protuberans and showing bimodal CD34+ fibroblastic and FXIIIa+ histiocytic immunophenotype.
Silverman JS; Tamsen A
J Cutan Pathol; 1998 May; 25(5):265-70. PubMed ID: 9696292
[TBL] [Abstract][Full Text] [Related]
35. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
36. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
Lee CS; Chou ST
Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
38. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.
Reimann JD; Fletcher CD
Am J Surg Pathol; 2007 Sep; 31(9):1371-7. PubMed ID: 17721193
[TBL] [Abstract][Full Text] [Related]
39. Palisading and verocay body-prominent dermatofibrosarcoma protuberans: a report of three cases.
Llatjós R; Fernández-Figueras MT; Díaz-Cascajo C; Ribera M; Ariza A
Histopathology; 2000 Nov; 37(5):452-5. PubMed ID: 11119127
[TBL] [Abstract][Full Text] [Related]
40. Dermatofibrosarcoma protuberans: a clinicopathological analysis of 10 cases in Asians.
Tan AW; Tan SH
Australas J Dermatol; 2004 Feb; 45(1):29-33. PubMed ID: 14961905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
